211 related articles for article (PubMed ID: 26404131)
1. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
Nakamura KD; Tilli TM; Wanderley JL; Palumbo A; Mattos RM; Ferreira AC; Klumb CE; Nasciutti LE; Gimba ER
Tumour Biol; 2016 Feb; 37(2):2655-63. PubMed ID: 26404131
[TBL] [Abstract][Full Text] [Related]
2. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
4. Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.
Tilli TM; Bellahcène A; Castronovo V; Gimba ER
BMC Cancer; 2014 Jun; 14():433. PubMed ID: 24928374
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin-c splicing isoform contributes to ovarian cancer progression.
Tilli TM; Franco VF; Robbs BK; Wanderley JL; da Silva FR; de Mello KD; Viola JP; Weber GF; Gimba ER
Mol Cancer Res; 2011 Mar; 9(3):280-93. PubMed ID: 21263033
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma.
Lin J; Myers AL; Wang Z; Nancarrow DJ; Ferrer-Torres D; Handlogten A; Leverenz K; Bao J; Thomas DG; Wang TD; Orringer MB; Reddy RM; Chang AC; Beer DG; Lin L
Oncotarget; 2015 Sep; 6(26):22239-57. PubMed ID: 26068949
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
Brum MCM; Dos Santos Guimaraes I; Ferreira LB; Rangel LBA; Maia RC; Nestal De Moraes G; Gimba ERP
Oncol Rep; 2021 Feb; 45(2):652-664. PubMed ID: 33416171
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin Splicing Isoforms Contribute to Endometriotic Proliferation, Migration, and Epithelial-Mesenchymal Transition in Endometrial Epithelial Cells.
Ho NT; Lin SW; Lee YR; Tzeng CR; Kao SH
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499654
[TBL] [Abstract][Full Text] [Related]
9. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.
Goparaju CM; Pass HI; Blasberg JD; Hirsch N; Donington JS
J Thorac Oncol; 2010 Oct; 5(10):1516-23. PubMed ID: 20689445
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.
Silva GR; Mattos DS; Bastos ACF; Viana BPPB; Brum MCM; Ferreira LB; Gimba ERP
Mol Biol Rep; 2020 Oct; 47(10):8339-8345. PubMed ID: 33006711
[TBL] [Abstract][Full Text] [Related]
11. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways.
Gimba ER; Tilli TM
Cancer Lett; 2013 Apr; 331(1):11-7. PubMed ID: 23246372
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
13. INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
Chen H; Li H; Chen Q
Biochem Biophys Res Commun; 2016 Aug; 477(3):467-72. PubMed ID: 27318090
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.
Sarosiek K; Jones E; Chipitsyna G; Al-Zoubi M; Kang C; Saxena S; Gandhi AV; Sendiky J; Yeo CJ; Arafat HA
J Gastrointest Surg; 2015 Apr; 19(4):639-50. PubMed ID: 25583441
[TBL] [Abstract][Full Text] [Related]
15. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.
Siddiqui AA; Jones E; Andrade D; Shah A; Kowalski TE; Loren DE; Chipitsyna G; Arafat HA
J Gastroenterol Hepatol; 2014 Jun; 29(6):1321-7. PubMed ID: 24548099
[TBL] [Abstract][Full Text] [Related]
17. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma.
Sullivan J; Blair L; Alnajar A; Aziz T; Chipitsyna G; Gong Q; Yeo CJ; Arafat HA
Histol Histopathol; 2011 Jul; 26(7):893-904. PubMed ID: 21630219
[TBL] [Abstract][Full Text] [Related]
18. Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer.
Hao C; Cui Y; Lane J; Jia S; Ji J; Jiang WG
Cells; 2021 Jul; 10(7):. PubMed ID: 34359989
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy.
Güttler A; Giebler M; Cuno P; Wichmann H; Keßler J; Ostheimer C; Söling A; Strauss C; Illert J; Kappler M; Vordermark D; Bache M
Radiother Oncol; 2013 Sep; 108(3):535-40. PubMed ID: 23891093
[TBL] [Abstract][Full Text] [Related]
20. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.
Wu J; Pungaliya P; Kraynov E; Bates B
Biomarkers; 2012 Mar; 17(2):125-33. PubMed ID: 22188260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
